M. Schenker

Statistics

Publications

Citations

H-Index

Active since

2023

Affiliations

Hospital Universitario 12 De Octubre(Current)

Universitat Autònoma de Barcelona

Hospital Universitario Virgen del Rocío

University of Medicine and Pharmacy of Craiova

Bristol-Myers Squibb (United States)

M. Schenker is an author at Hospital Universitario 12 De Octubre specializing in oncology, combination chemotherapy, and microsatellite instability subtypes.

Publications per year

2023–2025

Publications

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

E. Felip, C.I. Rojas, M. Schenker et al. · Annals of Oncology · 2025 · 28 citations · Full text

Medicine, Oncology, Pharmacology +13

LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study

N. Girard, Mauricio Burotto, L.G. Paz-Ares et al. · Annals of Oncology · 2024 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study

G. Folprecht, Thierry André, Elena Élez et al. · Zeitschrift für Gastroenterologie · 2024 · 14 citations

Medicine, Molecular Medicine, Oncology +12

OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

S.S. Ramalingam, T-E. Ciuleanu, R. Bernabe et al. · Journal of Thoracic Oncology · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

1–4 of 4